Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Prog Brain Res. 1998;117:267–85.

CAS  PubMed  Article  Google Scholar 

Audano M, Schneider A, Mitro N. Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration. J Neurochem. 2018;147:291–309.

CAS  PubMed  Article  Google Scholar 

Koh JY, Kim HN, Hwang JJ, Kim YH, Park SE. Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc. Mol Brain. 2019;12:18.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Nixon RA. The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. Biochim Biophys Acta Proteins Proteom. 2020;1868:140443.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325:473–7.

CAS  PubMed  Article  Google Scholar 

Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet. 2011;20:3852–66.

CAS  PubMed  Article  Google Scholar 

Martina JA, Diab HI, Lishu L, Jeong AL, Patange S, Raben N, Puertollano R. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7:ra9.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Collaborators GBDPsD. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.

Article  Google Scholar 

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.

CAS  PubMed  Article  Google Scholar 

Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583–90.

PubMed  Article  Google Scholar 

Forno LS. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol. 1996;55:259–72.

CAS  PubMed  Article  Google Scholar 

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40.

CAS  PubMed  Article  Google Scholar 

Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14:19–30.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19:170–8.

CAS  PubMed  Article  Google Scholar 

Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091–102.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257–72.

PubMed  Article  Google Scholar 

Luth T, Konig IR, Grunewald A, Kasten M, Klein C, Hentati F, Farrer M, Trinh J. Age at Onset of LRRK2 p.Gly2019Ser is related to environmental and lifestyle factors. Mov Disord. 2020;35:1854–8.

PubMed  Article  CAS  Google Scholar 

Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27–42.

CAS  PubMed  Article  Google Scholar 

Antony PM, Diederich NJ, Kruger R, Balling R. The hallmarks of Parkinson’s disease. FEBS J. 2013;280:5981–93.

CAS  PubMed  Article  Google Scholar 

Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80.

CAS  PubMed  Article  Google Scholar 

Langston JW, Irwin I, Langston EB, Forno LS. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett. 1984;48:87–92.

CAS  PubMed  Article  Google Scholar 

Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985;36:2503–8.

CAS  PubMed  Article  Google Scholar 

Ramsay RR, Salach JI, Singer TP. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun. 1986;134:743–8.

CAS  PubMed  Article  Google Scholar 

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119:866–72.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet. 1989;1:1269.

CAS  PubMed  Article  Google Scholar 

Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–7.

CAS  PubMed  Article  Google Scholar 

Schapira AH. Mitochondrial dysfunction in Parkinson’s disease. Cell Death Differ. 2007;14:1261–6.

CAS  PubMed  Article  Google Scholar 

Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 1989;26:719–23.

PubMed  Article  Google Scholar 

Mortiboys H, Thomas KJ, Koopman WJ, Klaffke S, Abou-Sleiman P, Olpin S, Wood NW, Willems PH, Smeitink JA, Cookson MR, Bandmann O. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol. 2008;64:555–65.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018;18:21.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem. 2017;143:418–31.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Buneeva O, Fedchenko V, Kopylov A, Medvedev A. Mitochondrial Dysfunction in Parkinson’s Disease: Focus on Mitochondrial DNA. Biomedicines. 2020;8(12):591.

CAS  PubMed Central  Article  Google Scholar 

Aomi Y, Chen CS, Nakada K, Ito S, Isobe K, Murakami H, Kuno SY, Tawata M, Matsuoka R, Mizusawa H, Hayashi JI. Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson’s disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function. Biochem Biophys Res Commun. 2001;280:265–73.

CAS  PubMed  Article  Google Scholar 

Keeney PM, Dunham LD, Quigley CK, Morton SL, Bergquist KE, Bennett JP Jr. Cybrid models of Parkinson’s disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol. 2009;220:374–82.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gaare JJ, Nido GS, Sztromwasser P, Knappskog PM, Dahl O, Lund-Johansen M, Maple-Grodem J, Alves G, Tysnes OB, Johansson S, et al. Rare genetic variation in mitochondrial pathways influences the risk for Parkinson’s disease. Mov Disord. 2018;33:1591–600.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Billingsley KJ, Barbosa IA, Bandres-Ciga S, Quinn JP, Bubb VJ, Deshpande C, Botia JA, Reynolds RH, Zhang D, Simpson MA, et al. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset. NPJ Parkinsons Dis. 2019;5:8.

PubMed  PubMed Central  Article  Google Scholar 

Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J. International Parkinson’s Disease Genomics C, Heutink P, Shulman JM: Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain. 2017;140:3191–203.

PubMed  PubMed Central  Article